



# Annual Report 2024

## Trustees' Report

For the year ended 30 June 2024

### What we do and why it matters

---

The British Society for Immunology is the UK membership organisation working with scientists and clinicians to forward immunology research and application around the world. Our ambitious and collaborative community consists of over 5,000 immunologists, giving us a powerful voice to advocate on immunological science and health for the benefit of society.

The Society supports its members, students and the wider public to learn more about immunology through disseminating research and providing resources, activities and grants to aid education in this field.

Immunological science underpins many aspects of human and animal health and disease, from communicable disease and vaccination to the management and treatment of many chronic conditions. Through enhancing our knowledge of how the immune system functions for the public benefit, the British Society for Immunology can play a key role in advancing Society's ability to prevent and treat disease.

### Our mission

---

The British Society for Immunology's mission is to support our immunology community in driving scientific discovery and making a positive impact on health.

We accomplish this by:

- Connected community: providing the immunology community with support to establish more connections and enhance collaboration, both within the field, and with other related scientific disciplines and between sectors.
- Championing careers: providing sector leading support to attract and retain talent in immunology.
- Catalysing change: influencing and improving the external environment to enable immunology to thrive and deliver positive outcomes for health.

The Trustees confirm they have referred to the Charity Commission's guidance on public benefit when reviewing the Society's aims and objectives, planning future activities and setting the annual operating plan.

## Our strategic objectives

The British Society for Immunology strategy sets our direction and priorities for 2021-2025.

Building on the strong foundations of our past work and guided by our updated vision and mission statements and set of values, this ambitious strategy lays out how we will work with our membership to deliver for the immunology and wider community over the coming years. As the UK's leading charity and scientific society representing the immune research sector, we are confident that we will fulfil this strategy to lead a positive change towards our vision of better health for all through immunology.



## Connected community

---

Our BSI community is at the heart of all we do. Being a member of the BSI means being a member of one of the largest immunology networks in the world. Immunology is a growing field, and the BSI aims to continually develop our activities and the support we provide to members to enable the discipline to flourish. Immunology intersects with numerous research fields, across different sectors, with the involvement of all career grades. Our goal is to bring this ecosystem together into a cohesive whole that fulfils our mission to take immunology forwards faster and more collaboratively.

Membership of the British Society for Immunology brings many benefits. These include discounts to our training courses, meetings and to our exceptional BSI Congress, access to a diverse range of grants, bursaries and prizes, free access to our journals and much more. The Society provides tailored support for our community through our highly valued Regional and Affinity Groups, but we are also there to represent immunology to the wider world. Members value our strong voice to speak out with influence and impact on behalf of immunology in policy, public engagement and the media.

At the end of June 2024, we had over 5,000 members, our highest ever membership, who join us from all walks of immunology. From students up to senior levels, they contribute to our work through many different routes, including speaking at our conferences, helping with our public engagement activities and advising on our policy work – our grateful thanks go to our whole immunology community.

In December 2023, over 1,400 immunologists came together in Belfast and online for our flagship event, BSI Congress 2023. It was an amazing four days of immunology, packed with cutting-edge science, inspiring debates and those all-important opportunities to connect and start new collaborations.

Our outstanding Keynote lecture was given by Professor Ronald Germain from the National Institutes of Health, USA on 'Visualising immunology – insights from multiplex dynamic and static tissue-scale imaging'.



Following the completion of the merger with the United Kingdom Primary Immunodeficiency Network (UKPIN) in 2022, the BSI Clinical Immunology Professional Network (BSI-CIPN) was created. This is an integrated and impactful professional network for individuals working within clinical immunology. The BSI-CIPN provides a strong voice for clinical immunology in policy, public affairs and supports the immunology community to network and engage with other across many disciplines.

At 30 June 2024, the BSI-CIPN had grown to over 150 members including consultant and trainee medics, healthcare scientists, nurses and pharmacists. The first full two-day BSI-CIPN conference took place at the ICC Belfast alongside the BSI Congress in December 2023. The event attracted over 220 participants from across the UK, including more than 35 people attending online.



### **Regional and Affinity Groups**

The BSI's Regional and Affinity Groups are a key part of the BSI community and are part of our core activity to bring our membership together. The scientific discussions and networking that take place via these Groups are invaluable for the continued development of immunology. Our 17 Regional Groups bring together immunologists within a local community, boosting local research networks. Our 12 Affinity Groups have all been created to focus meetings and discussions on specific areas of immunology and they continue to evolve as immunology expands its reach and knowledge.

Our Groups ran a full programme of activities this year with a huge amount of enthusiasm, dedication and expertise. Collectively, these events attracted over 2,500 delegates and played an important part in our strategy to develop our Regional and Affinity Groups as community-based expert hubs. Our Groups also ran several other activities including in-house seminar series, careers events and public outreach initiatives.

Highlights of the programme include:

The [BSI London Immunology Group](#) hosting a one-day meeting: Tissue Immunology 2023. This event attracted over 150 delegates as responses to infectious and inflammatory challenges within specific tissues were discussed.

The [BSI Neuroimmunology Symposium](#), a two-day meeting covering topics including brain injury, regeneration, peripheral neuroimmune mechanisms, neurodegenerative disease and CNS infection.

The third [Scottish Immunology Groups Network \(SIGNET\) joint symposium](#) held by the BSI Aberdeen, Edinburgh, Tayside and West of Scotland Immunology Groups. SIGNET was a full-day in-person symposium bringing together immunologists from across Scotland to share research, foster new collaborations and encourage networking. The event featured keynote speakers, Professor Leonie Taams and Professor Eduardo Villablanca.

In April 2024 the [BSI Immunometabolism Affinity Group](#) held a two-day event: Fuelling the immune response III. The keynote session on metabolic control of t cell function was given by Professor Russell Jones.

Another well attended event was the [BSI Oxford Immunology Group](#) in collaboration with the University of Oxford Immunology Network one day showcase of the fantastic research happening across Oxford. Topics covered included fundamental biology, infection, imaging to system immunology, therapeutics and AI.

The [BSI Tumour Immunology Group](#) held 'Revealing and tackling the complexities of the tumour microenvironment', a two-day event bringing scientific and clinical researchers alongside industry partners to examine and interrogate the multifaceted role of the immune system in the tumour microenvironment and to discuss how to harness these complexities.

Our Groups also ran several other activities including in-house seminar series, careers events and public outreach initiatives.

## BSI Journals



The BSI's original ethos still lies at the heart of our Society – to disseminate research with the aim of promoting and advancing immunology to foster future innovation. This has been a year of consolidation and growth for our highly respected family of three journals, *Clinical & Experimental Immunology*, *Immunotherapy Advances* and *Discovery Immunology*.

Working with our publishing partner, Oxford University Press, our journals aim to serve the field of immunology through publishing high-quality research articles, reviews, commentaries and short reports from researchers around the globe. We work closely with our Editors-in-Chief and Editorial Boards to take a strategic approach to ensure the continued high-performance of the journals. With our mixed portfolio of both hybrid and fully Open Access journals, the Society is in a strong position to continue to provide for the immunology community's publishing needs for many years to come.

In September 2023, the BSI journals hosted a webinar: Advances in Tissue Immunology. The Editors-in-Chief of all three BSI journals were joined by Professor Arnie Akbar and Dr Stephanie Dougan to discuss their recent research that has advanced our understanding of tissue immunology and immunity in health and disease. Over 160 people joined the webinar.

This year we also published a joint collection with articles from each of our family of journals.



Income generated from our journals provides major financial support for the Society's activities and we are hugely grateful to all our Editorial Board members for their ongoing commitment, and everyone who has contributed to the continued success of our journals, including authors, readers, reviewers and editors.



Our established high quality and translational research journal, *Clinical & Experimental Immunology* (*CEI*), continues to perform well with a solid impact factor of 3.4. This has been a busy year for the journal, led by Editor-in-Chief Leonie Taams, with several high-profile review series to take a deep dive into key topics including organoids to study immune cell development and function and unconventional T Cells.


**544 submissions**

**120 accepted articles**

The most viewed article published this year in *CEI* was titled Revolutionizing immune research with organoid-based co-culture and chip systems. It achieved approximately 3,000 total views from January to June 2024.

Other highlights include the Human B cells special issue, its top tweet collected 14,900 impressions. and the Unconventional T Cells in health and disease review series.





Other *CEI* articles published in the year topping 2,000 total views include Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy? and Interleukin-11 and its eminent role in tissue fibrosis: a possible therapeutic target.



Our first fully Open Access journal, *Immunotherapy Advances*, continues its progress to be a globally recognised title that both serves the immunotherapy community and exposes new developments in the field to a wide and diverse readership. Led by Editor-in-Chief, Tim Elliott, *Immunotherapy Advances* focuses on scientifically rigorous research relating to manipulations of the immune system for the benefit of human and animal health in all disease areas.

This year, the journal obtained its inaugural impact factor of 4.1 establishing it as a leading publication in the field of immunology.



The most read articles published in the year were Cancer vaccines: from an immunology perspective, and Strategies to overcome low MHC-I expression in paediatric and adult tumour, both published in December 2023 totalling 3,798 total views between them.

The most viewed article of the year was published in 2022-23. Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective by Shimon Sakaguchi, Ryoji Kawakami and Norihisa Mikami. This article was viewed over 3,000 times.





This was the first full year for *Discovery Immunology (DSI)*. This new fully Open Access journal, led by Editor-in-Chief Simon Milling, has a broad scope that focuses on new discoveries in cellular and molecular immunology. Over the course of the year, *Discovery Immunology* has reached several important milestones, including achieving indexing in PubMed Central and Scopus.

DSI published its first special collections, these help to increase the journal's profile and increase submissions made to the journal.



The most read article published this year was titled Deciphering the relationship between temperature and immunity, it collected almost 2,700 total views in the first six months since it was published.

Our focus for the next year is to continue building the submissions for the journal together with its reach and impact through publishing high-quality articles describing novel mechanisms of the immune response.

### **Supporting research consortia**

Under our current strategy, a new area of our work has been to support national and topic-specific research consortia efforts relevant to immunology. By championing investment in immunology and a 'team science' approach, we aim to use our skills to support cross-sector collaboration efforts to drive forward immunology research faster and more effectively.

We have built on our initial success this year by providing a variety of services to support several national research consortia including CARINA (Catalyst Reducing ImmuNe Ageing) Network, SIREN (SARS-CoV-2 Immunity and Reinfection Evaluation) study, PITCH (Protective Immunity from T Cells in Healthcare workers) and STRAVINSKY (Stratification of Clinically Vulnerable People for COVID-19 Risk Using Antibody Testing).



The CARINA (Catalyst Reducing ImmuNe Ageing) Network is a project funded by the Medical Research Council (MRC) and Biotechnology and Biological Sciences Research Council (BBSRC) and supported by the BSI. The network, which consists of over 100 researchers, clinicians and other stakeholders interested in the ageing immune system, aims to establish a UK-wide inclusive platform to enhance collaboration and foster knowledge exchange in the area of immune ageing as well as increasing the profile of the research area.

This year, we were delighted to successfully apply for a one-year funding extension for CARINA, allowing us to build the network's capacity and output. We ran CARINA's first ever grant round to provide flexible funding to early career CARINA members to support activities that help them develop their career in immune ageing. We were pleased to fund four grants as a result of this, covering a variety of activities including gathering pilot data, conference trips and external lab visits to learn new skills.

The annual CARINA Network meeting has also become a staple in the diary, bringing the immune ageing community together to gain a shared consensus of key research questions within immune ageing, facilitate cross-sector collaborations and strengthen our community. This year was no different with over 40 CARINA members in attendance. This time, we focused on providing slots for attendees to give 'elevator pitches' of their research to build knowledge of the skills and expertise within the Network.



This year, we have continued to support STRAVINSKY (Stratification of Clinically Vulnerable People for COVID-19 Risk Using Antibody Testing), which is funded by the National Institute for Health and Care Research (NIHR) and led by Professor Alex Richter. STRAVINSKY aims to build our understanding of who is most clinically vulnerable to COVID-19 infection and identify individuals or disease groups at highest risk. The study is investigating whether an antibody test result can predict an individual's risk of severe COVID-19 infection.

For this project, the BSI have recruited and are running their patient and public involvement (PPI) panel as well as assisting with external communications. The PPI Panel now meets regularly with the STRAVINSKY research team to ensure the expertise and viewpoints of the public contributors are fed directly into the research agenda. The PPI Panel's contributions are vital to ensuring the study's success.

## Keeping members informed

The BSI works hard to ensure good communication channels with our members, the wider immunology community and the public informed about our activities and about developments in immunology in the wider world.

*BiteSized Immunology*, our online resource designed to form a comprehensive guide to the immune system continues to be popular with some of the website's most visited pages.

Our social media channels continue to provide an important mode of engaging with our membership and the wider world at a more immediate level, to interact with our supporters and spread the word about our work and the wonders of immunology.

## Championing careers

---

The BSI provides several grant schemes to our members to support their work and their career development. These include a variety of activities – from covering the travel costs to conferences, to providing financial support for carers, support for public engagement initiatives and those that promote diversity and inclusion within immunology. We are very proud of the range of support we have been able to provide to members over the last 12 months.

**£192k grants  
awarded**

**286  
members  
supported**

## Career Enhancing Grants

Supporting current and future generations of immunologists throughout their careers is a vital part of our mission. This year has seen our Career Enhancing Grants go from strength to strength to support even more BSI members to reach their career goals. The scheme provides flexible financial support of up to £5,000 to allow individuals to build their skill set and advance their professional development.

**£79k  
Grants  
funded**

**21 members  
supported**

**Generate pilot data  
Training courses  
Lab visits**

## Mentoring scheme

Our highly successful mentoring scheme brings together senior scientists with early career researchers to assist the next generation of immunologist with career development and progression. The popularity of this scheme has flourished in recent years with a steady stream of applicants both mentors and mentees and many stories of successful career progression from past participants. This year, we have 23 pairs took part.

## **Bright Sparks in Immunology**

Our highly popular and prestigious 'Bright Sparks in Immunology' sessions at the BSI Congress aim to showcase the work of early career researchers as well as providing them with valuable experience talking about their work in front of a large audience. There are two categories (PhD and postdoc) with ten talks each, with the top three in each category winning a prize and being designated our 'Bright Sparks'.

Our judges are always astounded by the quality of talks and this year was no different. The future of immunology is certainly in good hands if the excellence within our Bright Sparks session is anything to go by and we were pleased to award the following winners.

## **Clinical immunology training days**

We partner with the Association of Clinical Pathologists (ACP) to run Clinical Immunology Training Days aimed at medical trainees in immunology and allergy, and immunology clinical scientists preparing to sit the Royal College of Pathologists in immunology exams.

By working together, the ACP and BSI ensure the continuous delivery of these highly valued training sessions, helping to create a new generation of immunology-aware and informed clinicians and clinical scientists across the NHS to improve the care and treatment of patients with immune-mediated disease. This year saw four events run in total (three in person and one online), covering the broad spectrum of the immunology curriculum. The training events themselves are consistently ranked as excellent by attendees who value the targeted content.

## **Training**

Our new training function went from strength to strength this year, building on past successes and with some exciting new courses launched and in the pipeline. Through our courses, we aim to provide tailored and innovative training to meet the needs of both immunologists, helping them keep their skills up to date and relevant, and non-immunologists, who want to understand the basics of the discipline to help in their jobs. This year, we had offerings applicable to all our members with courses in both the scientific and clinical spheres.

### **Bioinformatics**

This year, we had pleasure of building on the success of our bioinformatics training programme, which has been developed and is delivered by John Cole and Glasgow Bioinformatic Core. This suite of courses aim to equip wet-lab immunologists, biologists and other life scientists with the skills and confidence to perform their own bioinformatic data analysis. Bioinformatics is now a potent driver of scientific development and is fast becoming an essential skill for life sciences researchers. Particularly within immunology, it is also an area where there is currently a significant skills gap. To upskill our members and others working in relevant fields, we offer a range of high-quality and affordable bioinformatics courses, suitable for complete beginners through to advanced practitioners.

Across one entry level and two advanced courses, we trained a total of 324 scientists this year, with extremely positive feedback on the quality of the courses and how gaining these skills has helped to drive forward participants' careers.

**324 people  
trained**

## Immunotherapy in clinical practice

The last 15 years have seen new forms of immunotherapy introduced into almost every area of clinical practice. Following demand from within our community, we developed and delivered this new interactive training programme for individuals who are involved in the care of patients receiving immunotherapy. The modular online course provides essential immunology knowledge to demystify the science behind immunotherapy and explain the application of these therapies in the clinic.

This year, we piloted our first two modules, gastroenterology and rheumatology, both underpinned by an 'Immunology and immunotherapies 101' introductory module. During the courses, participants used problem-based learning to build their knowledge of how the basic science of the immune system relates to clinical practice, how immunotherapy drugs work, the pros and cons of different treatment options and the safety profile of the drugs and why treatment resistance and immune-related toxicities can occur. We had 16 people attend the gastroenterology course and 17 people on the rheumatology course, with positive feedback. We are taking the learnings from this pilot to develop further modules to launch in the coming year.

## Training in Patient & Public Involvement

As part of our work supporting the CARINA Network, we worked with the project's public contributors to update and re-run our online course for researchers on how to involve the public and patients in their research, and how to better understand the mindset and approach needed for effective and inclusive involvement. During the course, researchers were able to hear directly from PPI representatives as well as allowing for peer-to-peer learning through sharing experiences and case studies of successful involvement. The course was fully booked with 25 participants.

### Honorary members

Our honorary membership scheme recognises individuals who have made an outstanding contribution to immunology and/or to the Society. At BSI Congress 2023, we were delighted to award Lifetime Honorary Membership to two members:

- Professor Arne Akbar (University College London)
- Professor Allan Mowat (University of Glasgow)
- Professor Brigitta Stockinger (Francis Crick Institute)

## Catalysing change

---

### Public engagement

Our public engagement work over the last 12 months has focused primarily on vaccines. We have used a wide variety of methods and routes to engage with different communities to understand and answer their questions around vaccination.

### Resources for engagement

We have continued to develop a range of engagement resources around vaccines, including updating our highly rated comprehensive 'Guide to COVID-19 vaccinations' and creating an infographic to how the MMR vaccines works and why it is important that we are all vaccinated to protect against measles.

# Measles

British Society for  
**immunology**  
www.immunology.org

## What is measles?

Measles is a serious illness. It usually starts with cold-like symptoms then a rash. 1 in 5 children who catch measles need a hospital visit.

There is also the risk of very serious complications if it spreads to the lungs and brain.

**The MMR (Measles, Mumps and Rubella) vaccine is offered to young children to help protect against illness and to stop the spread of measles.**



## Who should get the MMR vaccine?

Measles is very infectious. In the UK, we aim for 95% of people to have the MMR vaccine. This stops the diseases spreading in our communities and protects those who can't have the vaccine (e.g. babies under 12 months).

Young children will be offered their first dose at 12 months and second dose at 3 years and 4 months, but adults can also have the vaccine if they weren't vaccinated as a child.

## Does the vaccine have side effects?

There can sometimes be mild side effects to the vaccine, like a rash or fever, but these only last a few days. More severe side effects are very rare and are monitored constantly.

The chance of complications from catching measles is a lot higher than any side effects you might experience from the vaccine.

**If you aren't sure if you've had the vaccine, get in touch with your GP.**



### Is there a link between the MMR vaccine and autism?

No. There has been lots of research and there is overwhelming evidence that there is no link.



### Why does my child need two doses of the MMR vaccine?

The first dose is to protect your child, and the second dose tops up that protection and helps to stop them spreading it.



### I'm worried about my child's immune system being overloaded.

Children's immune systems are exposed to lots of things in their everyday environment. The vaccinations they receive are only a small fraction of this and they help to protect against the most serious illnesses.

Sources: NHS, UKHSA, Green Book – Immunisation against infectious disease. Information correct as of March 2024.

**Find out more**

- BSI Guide to Childhood Vaccinations
- Talk to your GP or health visitor
- Look on the NHS websites
- Always use trusted sources



www.immunology.org

## #VaccineConversations

Empowering our members to engage with family, friends and communities to have meaningful conversations about vaccines has continued to be a core part of our work.

This year, we ran a stall at Lambeth Country Show, engaging with the public about how vaccines work and why they are important for health. Attendance at this event allows us to reach diverse communities in London. Using our interactive engagement activities and resources to draw people over to our stand, our wonderful volunteers had many interesting conversations and were able to increase the public's knowledge of the science behind vaccines.

### **Communication & Engagement Grants**

Our Communication & Engagement Grants have been a staple of BSI public engagement efforts over recent years and provide vital funding to allow our members to carry out engagement activities that strengthen understanding about immunology topics. The grants provide opportunities for our members to share their passion and knowledge for immunology and to build their confidence and skills in engaging with the public. We know our members hugely value these grants and we are very proud of all they achieve through their inspirational and innovative engagement plans.

### **Partnerships**

Working in partnership is a key part of the British Society for Immunology's strategy to build the impact that we can deliver for immunology. We engage with like-minded organisations to collaborate on areas of interest ranging from autoimmunity to cancer, to vaccines. By using our profile, expertise and reach, we can shine a light on the importance of critical areas of immunology to attract new focus and funding and build new collaborations between different sectors.

### **Policy highlights**

As always, the Society has continued to use our powerful voice to advocate for immunological science and health, ensuring the voice of immunologists is heard loud and clear in public debates and that policymakers have access to the latest immunological thinking. With our dynamic approach, working in partnership with BSI members and allied organisations, we have played a strong role in ensuring the expert voice of immunologists is represented in public debate.



## Enablers

---

To deliver our ambitious strategic aims, we need to maintain the BSI as a sector-leading organisation. We will do this by:


- Creating a larger and more diverse engaged membership
- Embedding quality, diversity and inclusion in all our activities
- Ensuring the Society's financial sustainability

### Enabler - membership

---

Our membership is the foundation of our Society. We are ambitious in what we want to deliver for immunology and for our members. As the discipline of immunology continues to grow and evolve, we aim to evolve too to ensure we engage with, support and are relevant to immunologists from across the spectrum of our community. As the largest professional immunology society in Europe and third largest in the world, we aim to stand shoulder to shoulder with our members to support and champion the discipline of immunology to drive scientific discovery and make a positive impact on health.

Membership numbers have consistently risen this year achieving record highs each month. This remarkable growth underscores the increasing value and appeal of our membership offerings, as more people recognise the benefits of joining the Society. In a significant milestone, we broke through the **5,000-member** mark for the first time in June 2024. Each month, we celebrate not just an increase in numbers, but a testament to our commitment to excellence and member satisfaction.



### **Providing the best service for our members**

One of our key aims is to ensure that increase our support and engagement with our members from all sectors and at all career stages. To support this work, this year we continued to develop our new membership management system to allow us to provide better, more joined up and holistic support and service for our members.

### **BSI Clinical Immunology Professional Network**

This is the second year of BSI Clinical Immunology Professional Network (BSI-CIPN) activities, following our successful merger with the UK Primary Immunodeficiency Network (UKPIN) in early 2023. Our aim is to run an integrated and impactful professional network, representing individuals working in all professions within clinical immunology.

The activities of the network are overseen by the BSI-CIPN Steering Group, chaired by Dr Sinisa Savic, supported by Deputy Chair Dr Suzanne Elcombe. The network welcomes members from all aspects of clinical immunology including doctors, scientists, nurses, pharmacists and trainees.



The network aims to foster closer links between clinical practitioners and basic scientists and strengthen the voice of clinical immunology in policy and public arenas. The BSI-CIPN will also share best practice through a range of resources and activities, including dedicated events, clinical sessions at BSI Congress, development of clinical guidelines, training provision and much more. By providing this strong platform for UK clinical immunology, our aim is to improve care for patients.

The activities of the network are overseen by the BSI-CIPN Steering Group, chaired by Dr Sinisa Savic, supported by Deputy Chair Dr Suzanne Elcombe. The network welcomes members from all aspects of clinical immunology including clinicians and trainees, nurses, healthcare scientists and pharmacists.

### **Developing the first strategy for BSI-CIPN**

This was a year of focusing on the future for the BSI-CIPN Steering Group, with the development of a new three-year strategy for BSI-CIPN, which lays out how we plan to support our members, and the wider professional and patient community, to be a strong voice and advocate for clinical immunology. The mission of the BSI-CIPN is to lead the delivery of excellence in patient care in clinical immunology, through three themes: education & training, advocacy & engagement, and research. This is an exciting step forward for the network and provides a roadmap to follow our ambition to be the 'go to' organisation for matters relating to clinical immunology in the UK. The strategy will be launched in 2024-25.

## BSI-CIPN conference

This was the first year of our official BSI-CIPN Conference, which brings the clinical immunology community together to discuss important clinical and research topics related to the healthcare of patients with primary immunodeficiencies, as well as a wide range of other topics relevant to clinical immunology practice, covering the latest thinking around key medical, scientific, educational and management issues relevant to all those working in the field.

Held alongside the BSI Congress in Belfast, this hugely successful event attracted over 240 participants from six countries, including more than 39 people attending online.

## Immunology News

Members in the UK can receive a printed copy of our quarterly membership magazine, *Immunology News*, with online access around the world. Immunology News amplifies the voice of our membership and highlights how we're supporting our members and representing immunology on a wider stage.



Over the last year editions featured, women in immunology, the scientific potential of immunogenicity, the CARINA (immunity for life) project, the Edinburgh Immunology EDI Summer School, highlights from the Parliamentary Links Day 2023, celebration of recent recipients of the BSI's teaching awards, the journey of a deaf immunologist, public engagement, HAE UK and we celebrated our new trustees, secretaries and committee members.

The March issue included an introduction to the fascinating field of ecoimmunology, which draws from both ecology and immunology to explore how the immune system functions in the real world.

This year also included a recap of highlights from BSI Congress 2023 and the 2023 BSI-CIPN conference.

## Corporate members

We would like to thank our corporate members whose continuous support enables us to undertake our work



## Enabler - Equality, diversity and inclusion

---

The BSI works hard to ensure that diversity and inclusion is at the heart of the ethos of our community. This year, we have continued to build on the promises laid out in our 'Diversity and Inclusion Framework', which outlines our commitment to how we are going to work with our members and community to ramp up our equity, diversity and inclusion work and respond to members' needs. By building on past and ongoing activities, this framework sets out our long-term plan of action for diversity and inclusion at the BSI.

This year, we have consolidated our progress to date as well as building on our EDI commitment further. As always, listening to and engaging with our members forms an important part of this scheme of work, making sure we understand their views of the BSI's role in supporting EDI in immunology, what we're doing well and what we could do better.

We continue to champion EDI through all our communication and particularly in our membership magazine, Immunology News, where we have run several high-profile case studies from different individuals on their experience of working in immunology and from projects funded through our EDI Activity Grant. Our Carers' Grants, that we offer for BSI Congress and for Regional and Affinity Group events, continue to be well received by the community, with impressive uptake, particularly for BSI Congress. We also ran a session at BSI Congress on research culture, with a panel of expert speakers to discuss and get feedback from attendees on good research culture practice and where there is still room for improvement within immunology. Finally, we have been engaging deeply with the wider scientific community to spread best practice on how we developed our framework and to learn from their experiences of similar activities.

### Income diversification

To deliver our ambitious strategic plans, we need to maintain the BSI as a sector-leading organisation, and one of the crucial enablers to do so is our financial sustainability. While traditionally we have relied heavily on our journal income to fund charitable activities, our shift to bring in new long-term and stable income sources is now well under way. The development of new income streams is never a quick process as there is often a delay between investment and return, requiring the use of reserves. However, our strong reserves have been built up for exactly this purpose – to support the organisation through this transition – and their use is now carefully planned.

### Consolidating our approach

This has been a year of consolidation in terms of our income diversification activities as we capitalise and build on the successful launch of new products and activities from previous years. Our new, modernised journals offering continues to go from strength to strength, reducing our financial reliance on the traditional subscription model while meeting the needs of our members and wider immunology community. Our two Open Access journals, *Immunology Advances* and *Discovery Immunology*, continue to prove a popular publication option and are meeting their key milestones. We were delighted that *Immunotherapy Advances* achieved its first ever impact factor of 4.1 in June 2024. Combined with the success of our well-established journal, *Clinical & Experimental Immunology*, we are well on course to stabilise our future journals income.

Meanwhile, we have built up a strong reputation within the sector for assisting the smooth running, effectiveness and impact of large research consortia. Prestigious projects we have worked on over the last 12 months include SIREN (SARS-CoV-2 immunity and reinfection evaluation) study, the CARINA (Catalyst Reducing ImmuNe Ageing) Network and STRAVINSKY (Stratification of Clinically Vulnerable People for COVID-19 Risk Using Antibody Testing) – see page 10 for more details. Our participation in this type of funded project continues to be an important source of income while allowing us to meet our wider goal of supporting the national immunology research effort. We have also maintained a future focus in this work, looking for upcoming opportunities to collaborate with the immunology research community to drive forward scientific discovery to have a positive impact on health.

We also continue to enhance our partnership and sponsorship areas of work with industry, establishing mutually beneficial routes for collaboration to highlight, celebrate and champion the immunology sector, which has been core to our strategic development of this area of work.

### Training achievements

A key success this year has been our BSI training function, which we launched at the start of 2023 with the aim of supporting immunologists and the wider research community keep their skills up-to-date and relevant.

This year, we launched several new courses, aimed at different sections of the research and clinical community. This included our much anticipated ‘Immunotherapy in clinical practice’ course, with modules focused on rheumatology and gastroenterology, and our collaboration with University of Birmingham on training on immune checkpoint blockade therapy.

Our training on bioinformatics, delivered in partnership with Glasgow Bioinformatic Core, has built an exceptional reputation amongst the research community and courses continue to be highly popular with very positive feedback. Throughout the year, we launched a number of new and/or updated modules as part of this training, which have been well received. We are delighted that these courses fulfil such a key training niche for researchers and are an excellent example of how our income diversification activities can align to provide much needed services for our immunology community.

## Structure, Governance and Management

---

### Charitable status and administrative details

The Society was registered as a charity in 1966 (Charity number 1043255) and incorporated in England and Wales as a company, limited by guarantee (Company number 03005933). The Society's registered address is 9 Appold Street, London EC2A 2AP. It has no share capital and the liability of its members is limited to a sum not exceeding £1. The Society's governing document is the Memorandum and Articles of Association, which was amended on 7 December 2016.

It is also a registered charity in Scotland (Charity number SC047367).

### Board of Trustees

The Trustees are company directors for the purposes of the Companies Act and charity Trustees for the purposes of the Charities Act 2011. The current trustees, and any past Trustees who served during the year are listed on page 55.

The Trustees are responsible for directing the Society's activities and for overseeing the management of the affairs of the Society, they delegate the day-to-day management of the organisation to the chief executive and the senior management team. The Board acts on advice and information from regular meetings with the chief executive and the senior management team.

As part of their induction process, Trustees spend some time with the chief executive and senior management team. They are provided a trustee resource pack containing the history of the Society and key information they require to fulfil their duties as Trustee, they are also offered training for new Trustees.

The success of the Society belongs in part to the large number of people who generously volunteer their time to add their experience to our collection of committees, we thank you all.

### Finance Sub Committee

The Finance Sub Committee ensures the system of internal control is satisfactory to deliver regulatory compliance, financial probity, value for money, challenge of financial plans, budgets and financial statements, oversight of the annual financial audit, review of investment policy and performance, review of reserves policy, and CEO and staff remuneration.

## **Nominations Committee**

The BSI's Nominations Committee has general oversight concerning the structures and effectiveness of BSI Board of Trustees, committees, advisers and observers. It is also responsible for nominating individuals to represent the views of the BSI on external committees and to identify BSI members to nominate for external awards.

## **Member Representative Forum**

The Membership Representative Forum represents a diverse mix of immunologists from different career stages, backgrounds and geographic locations, it is the BSI's 'think tank' and the place where issues and ideas that are of importance to the Society and its member are raised, discussed and developed.

## **Congress Committee**

The Congress Committee is responsible for the planning and delivery of the BSI's flagship event, BSI Congress, which takes place two out of every three years. It reviews and approves the scientific programme for Congress.

## **BSI-CIPN Steering Group**

The BSI-CIPN Steering Group directs the activities of the BSI-CIPN. The group consists of both elected (from the BSI-CIPN members) and co-opted immunology professionals (chosen because of their roles in other key organisations).

## **Group structure**

The Society has two wholly owned subsidiaries:

BSI Trading Limited is registered in England and Wales under company registration number 010201739. Its principal activity is to manage the corporate membership, sponsorship, exhibition, training and other trading activities for the Society.

The United Kingdom Primary Immunodeficiency Network (UKPIN) is a registered charity (1164466) and a company registered in England and Wales (09273983). The Activity in this company was wound down during the year following the transfer of its activities to the Society's Clinical Immunology Professional Network (BSI-CIPN).


## **Financial Performance**

The BSI continued our transition period following the changes to our publishing portfolio. The annual net deficit reduced by 62% from £0.41m last year to £0.16m this year. The operating deficit before movements in investment valuations was better than budget.

Publishing income remains the BSI's largest source of income, however after two years of reductions, it increased to 36% of total BSI income this year from 31% in 2022. This is the result of better performance of *CEI*.



The main sources of income are shown below:



The Society continued our success obtaining funding for our work supporting immunology research. Grants and donations fell 55% to £0.19m as a result of the £0.18m one-off donation received last year following the merger with UKPIN.

Income for BSI-CIPN more than doubled as it held its first two-day conference together with the BSI Congress.

In its second year, the BSI training function continued developing new courses, income for the year rose 138% to £66k. It is anticipated this will grow into significant future income stream for the Society.

Increased sales of exhibition space and sponsorship at Congress, the BSI-CIPN Conference and a rollout of more training courses pushed BSI Trading Limited to an annual profit of £0.56m (2023: £0.49m). This was gifted to the Society.

The United Kingdom Primary Immunodeficiency Network (UKPIN) posted a loss of £2k for the year (2023: £5k).

The Society is in a transition period following the reduction in journal income. The Society has been and will continue to focus on developing new income streams; however, this will require investment from our reserves. During this period, we are forecasting costs to exceed income over the next few years until the new income streams start generating significant levels of income.

### Investment policy and performance

The Society operates an investment policy to provide income and generate capital growth. The Society is a long-term investor and the value of its investments remains significant above its original investment.

As planned the BSI commenced our programme of drawdowns from investments as we invest in new sources of sustainable income. During the year £0.65m was withdrawn from our investments to help meet the BSI's cash requirements (2023: £1m). Future drawdowns are now estimated to be lower than originally forecast.

Funds are invested with LGT Wealth (formerly abdrn) with a long-term objective to generate a capital return of 3% more than inflation over a three-year rolling period. The performance of the BSI investment portfolio was buoyed by tech stocks which led to a significant rise in investments values. This produced a gain on investments for the year of £0.34m (2023: £0.007m loss). The value of the portfolio fell by £0.23m (2021: fall of £0.94m) significantly less than the drawdowns due to the rise in investment values. On 30 June 2024 investments were valued at £3.07m (2023: £3.30m).

The Finance Sub Committee is responsible for reviewing investment performance and policy.

## Reserves policy

The BSI operates a risk-based approach to reserves to ensure the BSI holds the most appropriate level of reserves to cover potential risks and to fund investment in new income sources securing the BSI's long term financial health.

Free reserves represent unrestricted general funds of the Society and exclude both restricted funds and funds that have been designated by the Board of Trustees. The free reserves also exclude any funds that could only be realised by disposing of fixed assets held for charitable use. Details of restricted funds can be found in note 15 of the accounts with details of designated funds in note 16.

	30 June 2024	30 June 2023
	£m	£m
<b>Total reserves</b>	3.74	3.90
Less: Fixed assets	(0.10)	(0.13)
Designated funds	(0.40)	(0.55)
Restricted funds	(0.25)	(0.26)
<b>Free reserves</b>	<b>2.99</b>	<b>2.95</b>

The BSI risk register is reviewed annually with monetary values allocated to specific risks to produce the required 'risk-adjusted' reserves level.

	30 June 2024
	£m
Income diversification development costs	0.77
Potential devluation of investment portfolio	0.65
Three momths operating costs	0.59
<b>Risk-adjusted' reserves</b>	<b>2.01</b>

The Society's free reserves are £0.98m more than the 'risk-adjusted' reserves level. The Society consider this is a sufficient provision for unknown risks (to give cover for those risks which the Society is not yet aware) and to fund future income generation opportunities.

## Pay policy

The Society's pay policy aims to ensure that all employees are paid at least the market median for their roles with the ability of high performers to move towards the upper quartile.

Salaries, including the Senior Management Team, are reviewed by the Finance Sub Committee with recommendations for the annual pay rise proposed to the wider Board of Trustees for approval as part of the annual budgeting process. The salary of the Chief Executive is reviewed annually by the Board of Trustees.

To increase transparency the Society's is voluntarily reporting its gender pay gap. Calculated in June 2024 the Society's mean gender pay gap is 40.38% (June 2023: 35.19%). The pay gap indicates that while 80% of employees are women (2023: 75%), most men are in management roles. The Society employs more women in each of the quartile pay bands.

The Society strongly supports equal pay, with individuals with the same responsibilities being paid the same irrespective of gender.

## Risk management

Good risk management is fundamental to the continued work and sustainability of the Society. We identify and manage risks that could adversely impact the achievement of our strategic purpose and determine the calculated risks we need to take to succeed.

The Society operates a formal framework for the management of risk, taking the view that risk can be positive (opportunity) or negative (threat). The Society operates a risk register incorporating strategic, operational and compliance risks, which are informed by the Society's strategic objectives, performance, voice of our stakeholders, regulatory environment and analysis of the external environment.

The Board delegates day-to-day responsibility for risk management to the Senior Management Team, who are responsible for identifying and evaluating risks to their areas and activities implementing appropriate controls for ongoing mitigation and monitoring.

The Financial Sub Committee reviews the management of risk in detail at each meeting and the Board reviews the Society's strategic and compliance risks twice a year.

The principal risks and uncertainties facing the society and the mitigations that we have put in place are as follows:

Risk: short term	Risk response
<b>Development of new surplus generating training function</b>	<p>Several courses are in development with some scheduled to be delivered in the coming months including the immunology nurses' training course.</p> <p>Additional modules are being developed for our successful Bioinformatics training programme. We will perform a thorough review of performance and feedback of launched courses.</p>
<b>Employee/Team capacity</b>	<p>Watching brief, with line managers ready to help team members when workload issues arise.</p> <p>SMT are committed to regularly proactively discussing reviewing our plan of activities and team capacity. The BSI team is now fully recruited.</p>

Risk: long term	Risk response
<p><b>Failure to find new sources of long-term sustainable income</b></p>	<p>The Society is proactively looking for new funding opportunities:</p> <ul style="list-style-type: none"> <li>▪ Working with partners and corporate members to develop existing and new sources of income</li> <li>▪ Developing a programme of training courses including training for nurses and a training course for clinicians.</li> </ul> <p>We are working to expand/grow the new activities launched in the last year</p>
<p><b>Loss of significant devaluation of investments</b></p> <p>A devaluation in the value of investments would result in a reduction of reserves available to use by the Society.</p> <p>Investments could be impacted by sudden unforeseen global events</p>	<p>The Society</p> <ul style="list-style-type: none"> <li>▪ Reviews investment performance during each Financial Sub Committee meeting</li> <li>▪ Communicates regularly with our investment managers, especially through times of significant volatility</li> </ul>

### Fundraising statement

Although the Society does not actively fundraise from members, occasional donations are received. The Society applies best practice in the tone of its communications and the accuracy of its data to minimise the pressures on supporters. The Society applies best practice to protect supporters' data, never sells or swaps it and ensures that communication preferences can be changed at any time. The Society commits to react to and investigate any complaints received, to learn from them and improve its service. During the year, the Society received no complaints about its fundraising activities.

## Future plans

During 2024-25 the Society will focus on:

### Connected community

- Launch and commence delivery of the first strategy for the BSI-CIPN
- Delivering a successful inaugural immune therapies summit

### Championing careers

- Successfully increase the careers support the BSI provides to members

### Catalysing change

- Continue and expand the BSI's successful partnership work
- Expanding the BSI's PPI activities through support of and inclusion in national research consortia

### Enabler - membership

- Launching targeted marketing campaigns to drive membership growth
- Grow membership of the BSI-CIPN

### Enabler - Equality, diversity and inclusion

- Collecting benchmark EDI data on BSI committees and creating a plan to further embed EDI in BSI activities

### Enabler - Financial sustainability

- Income diversification is a key priority: consolidation and expansion of current income generating activities and identifying and developing new sources of income including the launch and delivery of new training courses

The Senior Management Team and the Trustees continue to assess all significant risks, in the immediate, medium and longer term.

### Trustees' responsibilities

The Trustees (who are also directors of British Society for Immunology for the purposes of company law) are responsible for preparing the Trustees' report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Group and Society and of the income and expenditure of the Group and Society for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable to the United Kingdom and Republic of Ireland; and
- make judgements and estimates that are reasonable and prudent;
- state whether applicable United Kingdom Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume the charity will continue in operation.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the Group and Society and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and Society and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Each of Trustees confirm that:

- so far as the Trustee is aware, there is no relevant audit information of which the Group and Society's auditor is unaware; and
- the Trustee has taken all steps that he/she ought to have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the Group and Society's auditor is aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of s418 of the Companies Act 2006.

The Trustees are responsible for the maintenance and integrity of corporate and financial information included on the Society's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the Trustees and signed on their behalf by:



**Tracy Hussell**  
BSI President

Date: 16 October 2024

## Independent Auditor's Report to the members and trustees of the British Society for Immunology

### Opinion

We have audited the financial statements of the British Society for Immunology for the year ended 30 June 2024 which comprise the Group Statement of Financial Activities, the Group and Parent Charitable Company Balance Sheets, the Group Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

give a true and fair view of the state of the group's and the parent charitable company's affairs as at 30 June 2024 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;

have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011.

### Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs(UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

### Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.



In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

### **Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and  
the trustees' annual report have been prepared in accordance with applicable legal requirements.

### **Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the group and parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011 require us to report to you if, in our opinion:

the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or  
the parent charitable company's financial statements are not in agreement with the accounting records and returns; or  
certain disclosures of trustees' remuneration specified by law are not made; or  
we have not received all the information and explanations we require for our audit; or  
the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees' Annual Report and from preparing a strategic report.

### **Responsibilities of trustees**

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.

## **Auditor's responsibilities for the audit of the financial statements**

We have been appointed as auditor under Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, the Companies Act 2006 and Section 151 of the Charities Act 2011 and report to you in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

### **Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud**

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended), the Charities Act 2011, the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council

We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.

We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.

We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.

Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company's internal control.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.

Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

### **Use of our report**

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006; and to the charity's trustees, as a body, in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, and in respect of the consolidated financial statements, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters which we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company, the charitable company's members, as a body, and the charity's trustees, as a body for our audit work, for this report, or for the opinion we have formed.

*Moore Kingston Smith LLP*

Date: 9 December 2024

Neil Finlayson (Senior Statutory Auditor)  
for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

9 Appold Street  
London  
EC2A 2AP

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

**British Society for Immunology**  
Consolidated Statement of Financial Activities  
Year to 30 June 2024

		Unrestricted funds				
	Note	General funds £'000	Designated funds £'000	Restricted funds £'000	Total 2024 £'000	Total 2023 £'000
<b>Income from:</b>						
Grants and donations	2	-	-	191	191	425
Investments	3	115	-	-	115	132
Charitable activities	4					
Membership		172	-	-	172	162
BSI-CIPN		228			228	105
Partnership work		59	-	3	62	120
Congress		574	-	-	574	643
Meetings and events		79	-	-	79	83
Journals		844	-	-	844	749
Training		66	-	-	66	28
<b>Total income</b>		2,137	-	194	2,331	2,447
<b>Expenditure on:</b>						
<b>Raising funds</b>						
Investment management fees		29	-	-	29	35
Cost of raising funds		1	-	-	1	12
<b>Charitable activities</b>						
Membership		201	-	33	234	241
BSI-CIPN		217	-	-	217	80
Partnership work		136	-	-	136	147
Congress		636	-	-	636	720
Meetings and events		327	-	-	327	289
Journals		331	-	-	331	370
Training		38	77	-	115	94
Education and Careers		64	77	-	141	200
Diversity and inclusion		1	-	-	1	2
National Research support		-	-	114	114	129
Policy and Public Affairs		144	-	50	194	179
Public engagement		81	-	9	90	111
Communications		224	-	-	224	221
International work		40	-	-	40	23
<b>Total expenditure</b>	5	2,470	154	206	2,830	2,853
<b>Net income (expenditure) before gains (losses) on investments and transfers</b>						
		(333)	(154)	(12)	(499)	(406)
Net gains/(losses) on investments	12	340	-	-	340	(7)
<b>Net income/(deficit)</b>		<b>7</b>	<b>(154)</b>	<b>(12)</b>	<b>(159)</b>	<b>(413)</b>
<b>Reconciliation of funds:</b>						
Funds brought forward		3,086	553	258	3,897	4,310
Funds carried forward		<b>3,093</b>	<b>399</b>	<b>246</b>	<b>3,738</b>	<b>3,897</b>

There are no recognised gains or losses other than those recognised above. All activities are continuing.

The notes on pages 36 to 54 form part of these financial statements

**British Society for Immunology**  
Balance Sheet  
30 June 2024

		Group		Charity	
		2024	2023	2024	2023
<b>Fixed assets</b>					
Tangible fixed assets	10	38	53	38	53
Intangible assets	11	61	79	61	79
Investments	12	3,072	3,299	3,079	3,306
		<b>3,171</b>	<b>3,431</b>	<b>3,178</b>	<b>3,438</b>
<b>Current assets</b>					
Debtors	13	406	692	939	1,225
Cash at bank and in hand		734	578	138	25
		<b>1,140</b>	<b>1,270</b>	<b>1,077</b>	<b>1,250</b>
<b>Liabilities:</b>					
Creditors: amounts falling due					
within one year	14	(573)	(804)	(510)	(788)
<b>Net current assets</b>		<b>568</b>	<b>466</b>	<b>567</b>	<b>463</b>
<b>Net assets</b>		<b>3,738</b>	<b>3,897</b>	<b>3,745</b>	<b>3,900</b>
<b>Funds:</b>					
Unrestricted funds					
General fund		3,093	3,086	3,100	3,089
Designated fund	16	399	553	399	553
		<b>3,492</b>	<b>3,639</b>	<b>3,499</b>	<b>3,642</b>
Restricted funds	15	246	258	246	258
<b>Total</b>		<b>3,738</b>	<b>3,897</b>	<b>3,745</b>	<b>3,900</b>

As permitted by s408 Companies Act 1948, the company has not presented its own income and expenditure statement and related notes. The company's loss for the year was £156,238 (22/23 FY: £409,171).

These financial statements have been prepared in accordance with the provisions applicable to the small companies regime.

These accounts were approved by the Board and authorised for issue on 16 October 2024 and were signed on its behalf by:



**Tracy Hussell, President**

British Society for Immunology, Company Limited by Guarantee  
Company Registration Number 03005933 (England and Wales)

**British Society for Immunology**  
**Consolidated Statement of Cash Flows**  
**30 June 2024**

	<b>2024</b>	2023
	<b>£'000</b>	£'000
<b>Cash flows from operating activities:</b>		
<i>Net cash provided by operating activities</i>	<b>(524)</b>	<b>(893)</b>
<b>Cash flows from investing activities:</b>		
Income from investments	115	132
Purchase of tangible fixed assets	0	(21)
Proceeds from the disposal of investments	1,075	1,669
Purchase of investments	(501)	(933)
<b>Net cash used in investing activities</b>	<b>689</b>	<b>847</b>
<b>Change in cash and cash equivalents in the year</b>	<b>162</b>	<b>(46)</b>
Cash and cash equivalents at 1 July 2023	591	637
<b>Cash and cash equivalents at 30 June 2024</b>	<b>753</b>	<b>591</b>
<b>Net income for the period (as per the statement of financial activities)</b>	<b>(159)</b>	<b>(413)</b>
<b>Adjustments for:</b>		
Depreciation charge	34	30
(Gains) losses on investments	(340)	7
Investment income	(115)	(132)
(Increase) decrease in debtors	286	(140)
Increase (decrease) in creditors	(230)	(245)
<b>Net cash provided by operating activities</b>	<b>(524)</b>	<b>(893)</b>
<b>Analysis of cash and cash equivalents</b>		
Cash at bank and in hand	734	578
Cash held by investment managers	19	13
<b>Total cash and cash equivalents</b>	<b>753</b>	<b>591</b>

The notes on pages 37 to 55 form part of these financial statements

## Notes to the financial statements

### 1 Accounting policies

The principle accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

#### Basis of preparation

The financial statements are prepared on a going concern basis, under the historical cost convention modified to include the recognition of listed investments measured at fair value, which is consistent with the prior year. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities ("The SORP"), the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011.

The British Society for Immunology ("The Society") meets the definition of a public benefit entity under FRS 102

#### General information

The Society is a charitable company incorporated in England and Wales (company number 03005933) and is a charity registered in England and Wales (charity number 1043255) and registered as a charity in Scotland (charity number SC047367). The Society's registered address is 9 Appold Street, London EC2A 2AP.

#### Critical accounting judgements and key sources of estimation uncertainty

The preparation of financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group and Society accounting policies. In the application of the accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying value of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision only affects that period, or in the period of revision and future periods if the revision affected current and future periods.

In the view of the Trustees, no assumptions concerning the future or estimation uncertainty affecting assets or liabilities at the balance sheet date are likely to result in a material adjustment to their carrying amounts in the next financial year.

#### Going concern

The financial statements are prepared on a going concern basis which assumes the Society and Group will continue to meet its liabilities as they fall due for a period of at least twelve months from the date of the approval of these accounts. The Trustees are monitoring the post pandemic impact on the Society and Group. This includes regular review of the impact on our members and resulting changes in focus of our activities to support them. Trustees review regular updates on performance against KPIs, rolling forecasts, the risk register and in depth financial reports.

The Society is expanding its activities for its members, including further development and rollout of new training courses and events. This together with the holding of significant levels of cash and investments result in the Trustees considering the Society and the Group to be a going concern.



## Notes to the financial statements

### Income

All income is recognised once the Society and Group has entitlement to income, it is probable that income will be received and the amount of income receivable can be measured reliably. Income of the Society is, where applicable, included net of Value Added Tax (VAT) and is allocated to the period to which it relates, carrying forward that part of the income relating to future accounting periods.

Investment income is recognised on a receivables basis and when the amount can be measured reliably.

### Expenditure

Liabilities are recognised as soon as there is a legal or constructive obligation committing the Society and Group to that expenditure, it is probable that settlement will be required and the amount of obligation can be measured reliably. Expenditure is recognised on an accruals basis as a liability is incurred, inclusive of VAT, which cannot be recovered.

Expenditure is allocated to a particular activity where the cost relates directly to that activity. The cost of overall direction and administration of each activity, known as "support costs" and comprising the salary and overhead costs of the central function is apportioned based on staff time attributable to Support costs also include governance costs, which comprise organisational administration and compliance with constitutional and statutory requirements. The allocation of support and governance costs is analysed in notes 7 and 8.

### Employee benefits

Short-term benefits including holiday pay are recognised as an expense in the period in which the service is received.

Termination payments are accounted for on an accruals basis and in line with FRS 102.

The Society contributes to a Group pension scheme, the assets of which are administered by Royal London Plc. They are defined contribution schemes. All contributed costs are accounted for on the basis of charging the cost of providing pensions over the period when the Society and Group benefits from the employees' service. The Society and Group has no further liability under the scheme.

### Leasing and hire purchase commitments

Rentals paid under operating leases are charged to the income and expenditure account on a straight line basis over the lease term. The Society holds no assets under finance leases or hire purchase contracts.

### Tangible fixed assets

Tangible assets are stated at cost less accumulated depreciation. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. The minimum threshold is £1,000. Depreciated is provided at 33% in order to write off each asset over its estimated useful life.

### Intangible fixed assets

Intangible assets are stated at cost less accumulated amortisation. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. The minimum threshold is £1,000. Amortisation is provided at 20% in order to write off each asset over its estimated useful life. Assets in the course of construction are not amortised.

## Notes to the financial statements

### Investments

Investments are a form of basic financial instrument and are initially shown in the financial statements at fair value. Movements in the fair value of investments are shown as net gains and losses in the Statement of Financial Activities.

Profits and losses on the realisation of investments are shown as realised gains and losses in the Statement of Financial Activities. Net gains and losses on investments are calculated between sales proceeds and their opening carrying values or their purchase price if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

The investment in the subsidiary undertaking is included at cost with provision being made for any permanent diminution in value.

### Financial instruments

#### I) Financial assets

Basic financial assets, including trade and other receivables, cash and bank balances, are initially recognised at transaction value and subsequently measured at amortised cost. Other financial assets, including investments, are initially measured at fair value. Financial assets are derecognised when:

- a) the contractual rights to the cash flows of the asset expire or are settled, or
- b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or
- c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Cash at bank and cash in hand includes cash and short-term highly liquid investments with a short maturity of three months or less.

#### II) Financial liabilities

Basic financial liabilities, including trade and other payables, are initially recognised at transaction price. Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Financial liabilities held at amortised cost comprise all creditors except social security and other taxes and provisions.

### Provisions

Provisions are recognised where the Society has a present legal or constructive obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Provisions are measured at the present value or the expenditures expected to be required to settle the obligation.

## Notes to the financial statements

### Fund accounting

Unrestricted funds are those funds available to the Society and Group for general purposes. They include funds designated by the Trustees for particular purposes where their use remains at the discretion of the Trustees. It is the policy of the Trustees to retain in unrestricted funds, amounts which in their judgement, can help to mitigate the short-term effects of income volatility; and retain as long-term investment funds to generate sufficient income to meet current and future operational activities of the Society.

Restricted funds are those funds available to the Society and Group restricted to a specific purpose or are subject to particular donor imposed conditions. Further information is available in the reserves section of the Trustees' report.

### 2 Income from grants and donations

			2024	2023
	Unrestricted	Restricted	Total	Total
	funds	funds	funds	funds
	£'000	£'000	£'000	£'000
Grants	-	191	191	217
Donations	-	-	-	208
<b>Total</b>	<b>-</b>	<b>191</b>	<b>191</b>	<b>425</b>

### 3 Income from investments and interest

			2024	2023
	Unrestricted	Restricted	Total	Total
	£'000	£'000	£'000	£'000
Listed investments				
Investment Income	111	-	111	131
Bank deposit interest	4	-	4	-
<b>Total</b>	<b>115</b>	<b>-</b>	<b>115</b>	<b>131</b>

### 4 Income from charitable activities

	Unrestricted	Restricted	2024	2023
	funds	funds	Total	Total
	£'000	£'000	funds	funds
	£'000	£'000	£'000	£'000
Member subscriptions	172	-	172	162
BSI-CIPN	228	-	228	105
Corporates and partnership income	59	3	62	120
Congress	574	-	574	643
Meetings and events	79	-	79	83
Journals	844	-	844	749
Training	66	-	66	28
<b>Total</b>	<b>2,021</b>	<b>3</b>	<b>2,024</b>	<b>1,890</b>

## Notes to the financial statements

### 5 Total expenditure

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2024 Total £'000
<i>Raising funds</i>				
Investment management fees	29	-	-	29
Fundraising	1	-	-	1
<i>Charitable Expenditure:</i>				
Membership	201	-	33	234
BSI-CIPN	217	-	-	217
Partnership work	136	-	-	136
Congress	636	-	-	636
Other meetings and events	327	-	-	327
Journals	331	-	-	331
Training	38	77	-	115
Education and Careers	64	77	-	141
Diversity and inclusion	1	-	-	1
National Research support	-	-	114	114
Policy and Public Affairs	144	-	50	194
Public engagement	81	-	9	90
Communications	224	-	-	224
International Work	40	-	-	40
<b>Total</b>	<b>2,470</b>	<b>154</b>	<b>206</b>	<b>2,830</b>

Allocation of support costs to charitable activities:

	Direct costs £'000	Support costs £'000	2024 Total £'000
<i>Raising funds</i>			
Investment management fees	29	-	29
Cost of raising funds	1	-	1
<i>Charitable activities</i>			
Membership	171	63	234
BSI-CIPN	170	47	217
Partnership work	89	47	136
Congress	576	59	636
Other meetings and events	265	63	327
Journals	260	70	331
Training	76	39	115
Education and Careers	126	16	141
Diversity and inclusion	1	-	1
National Research support	114	-	114
Policy and Public Affairs	162	31	194
Public engagement	59	31	90
Communications	138	86	224
International Work	40	-	40
<b>Total</b>	<b>2,278</b>	<b>552</b>	<b>2,830</b>

## Notes to the financial statements

### 5 Total expenditure (continued)

Support costs are as follows:

	2024 £'000	2023 £'000
Staff costs	235	220
Premises costs	43	38
Depreciation	22	22
IT and electronic communications costs	81	90
Other	126	108
Recruitment fees	25	11
Governance costs (note 6)	19	18
<b>Total</b>	<b>552</b>	<b>507</b>

Support costs have been allocated based on time spent by departments supporting the various activities.

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2023 £'000
<i>Raising funds</i>				
Investment management fees	35	-	-	35
Fundraising	12	-	-	12
<i>Charitable Expenditure:</i>				
Membership	241	-	-	241
BSI-CIPN	80	-	-	80
Partnership work	147	-	-	147
Congress	720	-	-	720
Other meetings and events	289	-	-	289
Journals	370	-	-	370
Training	35	59	-	94
Education and Careers	64	136	-	200
Diversity and inclusion	2	-	-	2
National Research support	-	-	129	129
Policy	21	-	158	179
Public engagement	73	-	38	111
Communications	221	-	-	221
International work	23	-	-	23
<b>Total</b>	<b>2,333</b>	<b>195</b>	<b>325</b>	<b>2,853</b>

## Notes to the financial statements

### 6 Governance costs

	2024	2023
	£'000	£'000
Auditor's remuneration - audit	18	14
Auditor's remuneration - other	1	4
<b>Total</b>	<b>19</b>	<b>18</b>

### 7 Net income before gains (losses) on investments

	2024	2023
	£'000	£'000
This is stated after charging:		
Staff costs (note 9)	1,224	1,229
Depreciation	34	30
Auditor's remuneration - audit	18	14
Auditor's remuneration - other	1	4

## Notes to the financial statements

### 8 Staff costs

Staff costs during the year were as follows:

	2024 £'000	2023 £'000
Wages and salaries	1,056	1,054
Social security costs	115	122
Pension costs	53	53
<b>Total</b>	<b>1,224</b>	<b>1,229</b>

The average monthly number of employees during the year was as follows:

Within wages and salaries there are termination payments of £39k (2023: £nil).

	2024	2023
Direct charitable activities	16	15
Administration of the charity	2	3
	<b>18</b>	<b>18</b>

Number of employees whose annualised emoluments fall within following ranges for the year:

	2024	2023
£60,001 - £70,000	-	1
£70,001 - £80,000	1	-
£80,001 - £90,000	1	2
£90,001 - £100,000	1	-
£140,001 - £150,000	1	1

Pension contributions for these employees were £24,794 (2023 - £22,601).

The number of staff for whom retirement benefits are accruing under money purchase pension schemes amounted to 19 (2023 - 19).

The Society considers its key management personnel comprise the Trustees and the Senior Management Team (SMT). The Trustees provide their time free of charge. The total remuneration, employer's national insurance contributions, benefits and pensions paid to the SMT was £513,859 (2023 - £524,335).

The relevant staff costs have been included in the costs of charitable activities. The gender split in the society workforce is 78% female 22% male (2023: 67% female 33% male). All roles are evaluated and paid in accordance with external benchmarking irrespective of gender.

### 9 Trustees' remuneration

No trustees received any remuneration for his or her services during the year (2023 - none). During the year expenses totalling £3,551 (2023 - £6,933) were reimbursed to 8 trustees (2023 - 14). In addition £3,160 was paid for travel and accommodation costs on behalf of trustees (2023: £9,293).

In May 2024 one trustee was awarded a career enhancing grant of £3,210. One trustee was paid £500 for his role in delivering part of the Immunology in Clinical Practice training course.

## Notes to the financial statements

### 10 Tangible assets of the Group and charity

	Website £'000	Computer equipment £'000	Total £'000
<b>Cost or valuation</b>			
At 1 July 2023	56	33	89
Additions	-	-	-
Disposals	-	(29)	(29)
At 30 June 2024	56	4	60
<b>Depreciation</b>			
At 1 July 2022	9	27	36
Charge for the year	11	4	15
Eliminated on disposal	-	(29)	(29)
At 30 June 2024	20	2	22
<b>Net book value</b>			
At 30 June 2024	36	2	38
At 1 July 2023	47	6	53

### 11 Intangible assets of the Group and charity

	IT software £'000	Total £'000
<b>Cost or valuation</b>		
At 1 July 2023	93	93
Additions	-	-
Disposals	-	-
At 30 June 2024	93	93
<b>Depreciation</b>		
At 1 July 2023	14	14
Charge for the year	18	18
Eliminated on disposal	-	-
At 30 June 2024	32	32
<b>Net book value</b>		
At 30 June 2024	61	61
At 1 July 2023	93	93

Construction of a new CRM system was completed during the year.



## Notes to the financial statements

### 12 Investments

	Group		Charity	
	2024	2023	2024	2023
	£'000	£'000	£'000	£'000
<b>Market value at 1 July 2023</b>	3,286	4,029	3,286	4,029
Disposals proceeds	(1,075)	(1,669)	(1,075)	(1,669)
Realised gains/(losses)	(3)	14	(3)	14
Additions at cost	501	933	501	933
Unrealised gains	343	(21)	343	(21)
<b>Market value at 30 June 2024</b>	3,052	3,286	3,052	3,286
Cash held with investment managers	19	13	19	13
Investment in UKPIN	-	-	7	7
<b>Total investments</b>	<b>3,072</b>	<b>3,299</b>	<b>3,079</b>	<b>3,306</b>

Total Group investments includes £100 investment in subsidiary.

	Group		Charity	
	2024	2023	2024	2023
	£'000	£'000	£'000	£'000
At 30 June 2024 the listed investments comprised the following:				
UK equities	715	816	715	816
Overseas equities	1,781	1,779	1,781	1,779
Investment instruments	556	691	556	691
<b>Total</b>	<b>3,052</b>	<b>3,286</b>	<b>3,052</b>	<b>3,286</b>
Historical cost of listed investments	2,324	3,317	2,324	3,317

Investments representing more than 5% of the total market value of the portfolio of listed investments are as follows:

	Cost	Market value	Portfolio
	2024	2024	%
	£'000	£'000	
Volare Offshore sterling fixed interest fund Z GBP (formerly Aberdeen Standard Capital Offshore Fixed Interest Fund Institutional)	210	191	6.19%

12 Investments (continued)

**Investment in subsidiary undertaking**

The Society has two wholly owned trading subsidiaries. A summary of their trading results are shown below.

BSI Trading Limited is incorporated in England and Wales, registered number 01021739. Its registered office is 9 Appold Street London EC2A 2AP. The principal activity of the company is the management of corporate membership, sponsorship, exhibition and other trading activities for the Society.

The Society become sole member of United Kingdom Primary Immunodeficiency Network (UKPIN) on 20 December 2022 and accordingly on that date UKPIN became a subsidiary of the group. During the year UKPIN transferred £175k to the Society being most of its net assets on the acquisition date.

UKPIN is incorporated in England and Wales, registered number 09273983. Its registered office is 9 Appold Street, London EC2A 2AP. The principal activity of the company was the advancement of health among those with primary immunodeficiency disorders and advancing education in PID and related subjects. These activities have been transferred to the Society's Clinical Immunology Professional Network (BSI-CIPN).

A summary of the results of the subsidiaries is shown below:

	2024			2023		
	BSI Trading Limited £'000	UKPIN £'000	Total £'000	BSI Trading Limited £'000	UKPIN £'000	Total £'000
Turnover	565	-	565	576	-	576
Operating costs	-	-	-	-	-	-
Operating profit	565	-	565	576	-	576
Administration costs	(51)	(2)	(53)	(87)	(5)	(92)
Profit(loss) for the financial period	514	(2)	512	489	(5)	484
Distribution to parent charity	(514)	-	(514)	(489)	(175)	(484)
<b>Retained in subsidiary</b>	<b>-</b>	<b>(2)</b>	<b>-</b>	<b>-</b>	<b>(180)</b>	<b>-</b>

The assets and liabilities of the subsidiaries were:

Assets	601	-	601	600	2	602
Liabilities	(601)	-	(601)	(600)	-	(600)
<b>Net assets</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2</b>	<b>2</b>

## Notes to the financial statements

### 13 Debtors

	Group		Charity	
	2024	2023	2024	2023
	£'000	£'000	£'000	£'000
Trade debtors	127	389	72	425
Prepayments and accrued income	262	303	262	303
VAT receivable	17	-	17	-
Amount owed by subsidiary undertaking	-	-	588	497
<b>Total</b>	<b>406</b>	<b>692</b>	<b>939</b>	<b>1,225</b>

### 14 Creditors

	Group		Charity	
	2024	2023	2024	2023
	£'000	£'000	£'000	£'000
Trade creditors	142	74	92	74
Other taxes and social security costs	30	40	30	40
VAT payable	-	9	-	9
Other creditors	133	177	133	177
Accruals and deferred income	268	504	255	488
<b>Total</b>	<b>573</b>	<b>804</b>	<b>510</b>	<b>788</b>

Included within the above is deferred income as set out below:

	Group	Charity
	2024	2024
	£'000	£'000
Deferred income brought forward at 1 July	459	422
Additional income deferred during the year	181	169
Brought forward funds released in the year	(459)	(422)
<b>Deferred income carried forward at 30 June</b>	<b>181</b>	<b>169</b>

Deferred income comprises advance payments of journal royalties and memberships fees.

## Notes to the financial statements

### 15 Restricted funds

	At 1 July 2023	Income	Expenditure	At 30 June 2024
Meeting funds	34	-	(34)	-
BSI-CIPN	178	-	-	178
Ageing and immunity	28	68	(96)	-
SIREN	-	8	(8)	-
STRAVINSKY	14	-	(12)	2
Visiting Scholar and Jonathan Sherrard Awards	4	-	-	4
mRNA project	-	50	(50)	-
PITCH	-	7	(7)	-
Nursing training	-	62	-	62
<b>Total</b>	<b>258</b>	<b>194</b>	<b>(206)</b>	<b>246</b>

#### Meeting funds

Donations to the Society by individuals to promote certain immunological issues.

#### BSI-CIPN

Funds transferred from UKPIN upon the merger to be used to promote and support clinical immunology through the BSI-CIPN

#### Ageing and immunity

The CARINA (Catalyst Reducing ImmuNe Ageing) Network is a new collaborative network for researchers working on the immune system throughout the life course. The BSI has a leading role in supporting the network through provision of project management, events support, communications expertise and patient and public involvement (PPI).

#### SIREN

Recruitment, facilitation and reporting of findings from Patient and Participant Involvement workshops for the SIREN project funded by the UK Health Security Agency.

#### STRAVINSKY

Funds to support a 2 year study aiming to establish if antibody testing can identify who remains at greatest risk of severe COVID-19 infection after vaccinations.

#### PITCH

The PITCH (Protective Immunity from T Cells in Healthcare workers) is a project seeking to understand the role of T cell immunity in protection against COVID-19 in healthcare workers. The BSI is supporting the project by leading its participant Involvement Panel to ensure the research is relevant, suitable and valuable.

#### Nursing training

Project to develop and provide immunology training for nurses. This is funded by CSL Behring UK Limited and Biocryst US Sales Co LLC.

## Notes to the financial statements

### 15 Restricted funds (Continued)

#### UK-CIC

A grant for the BSI support provided to the UK Coronavirus Immunology Consortium (UK-CIC) to understand the immunology of SARS-CoV-2 and COVID-19.

#### Vaccine taskforce

Funding from the European Federation of Immunological Societies (EFIS) for the EFIS Vaccine Taskforce work led by the BSI.

#### Immunogenicity project

Immunogenicity measures in vaccine development and decision making programme funded by Merck Sharp & Dohme (UK) Limited.

#### UK Covid Vaccines Research Hub

Central co-ordination hub for COVID-19 immunology research investments and outcomes funded by UKRI via the National Core Studies programme.

#### Visiting Schloar and Jonathan Sherrard Awards

Funds to support members for periods of training in academic or clinical centres to further their knowledge of primary immunodeficiencies.

	At 1 July 2022 £'000	Income £'000	Expenditure £'000	At 30 June 2023 £'000
Meeting funds	34	-	-	34
BSI-CIPN	-	178	-	178
Autoimmunity	12	-	(12)	-
UK-CIC	-	63	(63)	-
Vaccine taskforce	1	25	(26)	-
UK Covid Vaccines research	61	63	(124)	-
Ageing and immunity	-	68	(40)	28
SIREN	8	9	(17)	-
Immunogenicity project	27	15	(42)	-
STRAVINSKY	-	15	(1)	14
Visiting Scholar and Jonathan Sherrard Awards	-	4	-	4
<b>Total</b>	<b>143</b>	<b>440</b>	<b>(325)</b>	<b>258</b>

### 16 Designated funds

	At 1 July 2023	Designated in year	Utilised / released	At 30 June 2024
Long term sustainability	98	-	-	98
Training	91	-	(76)	15
Career development programme	364	-	(77)	287
<b>Total</b>	<b>553</b>	<b>0</b>	<b>(154)</b>	<b>399</b>

## Notes to the financial statements

### 16 Designated funds (Continued)

#### Long term sustainability

The long term sustainability fund provides resources for investing in the financial sustainability of the charity over the next five years.

#### Training

Funding for the creation and development of a new surplus generating training function within the BSI.

#### CRM project

The CRM project fund provides resources to develop and implement a new CRM system together with an upgrade to the BSI website

#### Career development programme

The Career development programme will fund a significant expansion in the careers support the BSI offers to our members. This includes two main streams: our career-enabling activities and our career-enhancing activities.

### 17 Analysis of net assets between funds

				2024
	Unrestricted	Designated	Restricted	Total funds
Group	funds	funds	funds	
	£'000	£'000	£'000	£'000
Tangible fixed assets	38	-	-	38
Intangible assets	61	-	-	61
Investments	3,072	-	-	3,072
Current assets	494	399	246	1,139
Current liabilities	(573)	-	-	(573)
<b>Total Funds</b>	<b>3,091</b>	<b>399</b>	<b>246</b>	<b>3,737</b>

				2024
	Unrestricted	Designated	Restricted	Total funds
Charity	funds	funds	funds	
	£'000	£'000	£'000	£'000
Tangible fixed assets	38	-	-	38
Intangible assets	61	-	-	61
Investments	3,079	-	-	3,079
Current assets	432	399	246	1,077
Current liabilities	(510)	-	-	(510)
<b>Total Funds</b>	<b>3,099</b>	<b>399</b>	<b>246</b>	<b>3,745</b>

## Notes to the financial statements

### 17 Analysis of nets assets between funds (Continued)

The total unrealised gains (losses) as at 30 June 2023 constitutes movements on revaluation and are as follows:

	2024 £'000	2023 £'000
<b>Unrealised gains (losses) included above:</b>		
On investments	1,305	962
<b>Total unrealised gains (losses) at 30 June</b>	<b>1,305</b>	<b>962</b>
<b>Reconciliation of movements in unrealised gains (losses)</b>		
Unrealised gains at 1 July	962	983
Less: in respect to disposals in the year	-	-
	962	983
Add: net gains (losses) arising on revaluation arising in the year	343	(21)
<b>Total unrealised gains (losses) at 30 June</b>	<b>1,305</b>	<b>962</b>

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2023 Total funds £'000
<b>Group</b>				
Tangible fixed assets	53	-	-	53
Intangible fixed assets	79	-	-	79
Investments	3,299	-	-	3,299
Current assets	458	553	258	1,269
Current liabilities	(804)	-	-	(804)
<b>Total Funds</b>	<b>3,085</b>	<b>553</b>	<b>258</b>	<b>3,896</b>

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2023 Total funds £'000
<b>Charity</b>				
Tangible fixed assets	53	-	-	53
Intangible fixed assets	79	-	-	79
Investments	3,306	-	-	3,306
Current assets	440	553	258	1,251
Current liabilities	(788)	-	-	(788)
<b>Total Funds</b>	<b>3,090</b>	<b>553</b>	<b>258</b>	<b>3,901</b>

## Notes to the financial statements

### 18 Share capital

---

The company is limited by guarantee and therefore has no share capital. Each member's liability is limited to £1.

### 19 Related party transactions

---

Matthew Siggins was awarded a Career enhancing grants of £3,210 in May 2024 for two weeks of highly specialised training in lymphatic immunology.

James Brewer was paid £500 for his role in delivering the immunology in clinical practice training.

In 2022 The Kennedy Trust for Rheumatology Research (charity No. 260059) provided £5,000 sponsorship for the BSI awards. Professor Tracy Hussell is a trustee of this charity.

There were no other related party transactions that required disclosure in the current financial period (2023: none).



## Notes to the financial statements

### 20 Comparative consolidated statement of financial activities

	Unrestricted funds			
	General £'000	Designated £'000	Restricted £'000	2023 £'000
<b>Income from:</b>				
Donations	-	-	425	425
Investments	132	-	-	132
Charitable activities				
Membership	162	-	-	162
BSI-CIPN	105	-	-	105
Partnership work	105	-	15	120
Congress	643	-	-	643
Meetings and events	83	-	-	83
Journals	749	-	-	749
Training	28	-	-	28
<b>Total income</b>	<b>2,007</b>	<b>-</b>	<b>440</b>	<b>2,447</b>
<i>Raising funds</i>				
Investment Management Fees	35	-	-	35
Cost of raising funds	12	-	-	12
<i>Charitable activities</i>				
Membership	241	-	-	241
BSI-CIPN	80	-	-	80
Partnership work	147	-	-	147
Congress	720	-	-	720
Meetings and events	289	-	-	289
Journals	370	-	-	370
Training	35	59	-	94
Education and Careers	64	136	-	200
Diversity and inclusion	2	-	-	2
National Research support	-	-	129	129
Policy and Public Affairs	21	-	158	179
Public engagement	72	-	38	110
Communications	221	-	-	221
International work	23	-	-	23
<b>Total expenditure</b>	<b>2,333</b>	<b>195</b>	<b>325</b>	<b>2,853</b>
<b>Net income (expenditure) before gains (losses) on investments and transfers</b>	<b>(326)</b>	<b>(195)</b>	<b>115</b>	<b>(406)</b>
Net gains/(losses) on investments	(7)	-	-	(7)
Transfers between funds	23	(23)	-	-
<b>Net income</b>	<b>(310)</b>	<b>(218)</b>	<b>115</b>	<b>(413)</b>
<b>Reconciliation of funds:</b>				
Funds brought forward	3,396	771	143	4,310
Funds carried forward	3,086	553	258	3,897

## Notes to the financial statements

### 21 Charity statement of financial activities

	Unrestricted funds			Total	Total
	General funds	Designated funds	Restricted funds	2024	2023
	£'000	£'000	£'000	£'000	£'000
<b>Income from:</b>					
Grants and donations	-	-	191	191	425
Investments	115	-	-	115	132
Charitable activities					
Membership	172	-	-	172	162
BSI-CIPN	44	-	-	44	3
Partnership work	29	-	-	29	38
Congress	332	-	3	335	300
Meetings and events	38	-	-	38	49
Journals	844	-	-	844	749
Training	-	-	-	0	12
Gift Aid and recharge from BSI Trading Limited	564	-	-	564	575
<b>Total income</b>	<b>2,137</b>	<b>-</b>	<b>194</b>	<b>2,331</b>	<b>2,445</b>
<b>Expenditure on:</b>					
<b>Raising funds</b>					
Investment management fees	29	-	-	29	35
Cost of raising funds	1	-	-	1	12
<b>Charitable activities</b>					
Membership	201	-	33	234	242
BSI-CIPN	217	-	-	217	80
Partnership work	136	-	-	136	147
Congress	636	-	-	636	720
Meetings and events	327	-	-	327	289
Journals	331	-	-	331	720
Training	38	77	-	115	94
Education and Careers	64	77	-	141	200
Diversity and inclusion	1	-	-	1	2
National Research support	-	-	114	114	129
Policy and Public Affairs	143	-	50	193	171
Public engagement	80	-	9	89	111
Communications	221	-	-	221	221
International work	40	-	-	40	23
<b>Total expenditure</b>	<b>2,466</b>	<b>154</b>	<b>206</b>	<b>2,826</b>	<b>3,197</b>
<b>Net income (expenditure) before gains (losses) on investments and transfers</b>	<b>(329)</b>	<b>(154)</b>	<b>(12)</b>	<b>(495)</b>	<b>(752)</b>
Net gains/(losses) on investments	340	-	-	340	(7)
<b>Net income/(deficit)</b>	<b>11</b>	<b>(154)</b>	<b>(12)</b>	<b>(155)</b>	<b>(759)</b>
<b>Reconciliation of funds:</b>					
Funds brought forward	3,090	553	258	3,901	4,310
<b>Funds carried forward</b>	<b>3,101</b>	<b>399</b>	<b>246</b>	<b>3,746</b>	<b>3,551</b>

## Board of Trustees

Position	Trustee	Date of appointment / resignation
<b>Previous</b>		
Early Career Trustee	Dr Emma Chambers	Resigned June 2024
Co-opted Trustee	David Pemberton	Appointed July 2023 Resigned February 2024
Early Career Trustee	Dr Emma Chambers	Resigned July 2022

<b>Current</b>		
President	Professor Tracy Hussell	Appointed December 2022
Treasurer	Dr Fiona Culley	Re-appointed July 2021
Chair of Forum	Professor James Brewer	Appointed January 2023
Clinical Research Secretary	Professor Colin Dayan	Re-appointed June 2024
Co-opted Trustee	Robert Davies	Re-appointed July 2020
Trustee	Professor Deborah Dunn-Walters	Re-appointed July 2023
Co-opted Trustee	Dr Edith Hessel	Appointed January 2020
Trustee	Professor Teresa Lambe	Appointed January 2023
Co-opted Trustee	James Lowe	Re-appointed June 2023
Trustee	Dr Carolyn Nielsen	Appointed July 2024
Early Career Trustee	Dr Matthew Siggins	Appointed July 2022
Co-opted Trustee	Dr Sinisa Savic	Appointed July 2022
Trustee	Dr Divya Shah	Re-appointed July 2023
Trustee	Dr Jessica Strid	Appointed July 2023

## Leadership

### Board and Committee meetings and attendance

All Trustees are expected to attend each Board meeting and each Committee meeting for which they are members, unless there are exceptional circumstances preventing them from participating. The table below shows the attendance at Board and other BSI committees.

Trustees	Board	BSI-CIPN Steering Group	Congress Committee	Finance Sub Committee	Membership Representative Forum	Nominations Committee
Professor Tracy Hussell	4/4	-	3/3	-	3/4	1/1
Dr Fiona Culley	4/4	-	1/4	4/4	-	-
Professor James Brewer	3/4	-	-	-	4/4	1/1
Professor Colin Dayan	2/4	-	1/4	-	-	-
Dr Emma Chambers	3/4	-	-	-	-	-
Robert Davies	4/4	-	-	-	-	1/1
Professor Deborah Dunn-Walters	4/4	-	-	-	-	-
Dr Edith Hessel	4/4	-	1/1	-	-	1/1
Professor Teresa Lambe	2/4	-	-	-	-	1/1
James Lowe	4/4	-	-	4/4	-	-
David Pemberton	2/2	-	-	2/2	-	-
Dr Matthew Siggins	4/4	-	-	-	-	-
Dr Sinisa Savic	3/4	4/4	-	-	-	-
Dr Divya Shah	4/4	-	-	-	-	-
Dr Jessica Strid	3/4	-	-	-	-	-

### Senior Management Team

Name	Position
Dr Doug Brown	Chief Executive
Otto Balsiger	Director of Finance, Membership and Publishing
Dr Jennie Evans	Director of External Affairs
Jane Sessenwein	Director of Events & Training

## Principal professional advisers

Name	Advisor
Bankers	Bank of Scotland 14/16 Cockspur Street London EC2V 6DL
External auditors	Moore Kingston Smith LLP 9 Appold Street London EC2A 2AP
Investment advisers	LGT Wealth (formerly abrdn ) 14th Floor 30 St Mary Axe London EC3A 8BF
Solicitors	Russell Cooke LLP 2 Putney Hill London SW15 6AB

## Committees

### Nominations Committee

Members	
Professor Tracy Hussell	Chair, BSI President
Robert Davies	BSI Co-opted Trustee
Professor James Brewer	Trustee
Dr Edith Hessel	Trustee
Professor Teresa Lambe	Trustee
Dr Doug Brown	BSI CEO (observer)

### Finance Sub Committee

Members	
Dr Fiona Culley	BSI Treasurer
James Lowe	Co-opted Trustee
Dr Doug Brown	BSI Chief Executive
Otto Balsiger	BSI Director of Finance, Membership and Publishing

### Membership Representative Forum

Members	
Professor James Brewer	Chair
Professor Tracy Hussell	BSI President
Dr Colin Dayan	Clinical Research Secretary
Dr Sophie Rutschmann	Education & Careers Secretary
Professor Matthias Eberl	Public Engagement Secretary
Dr Doug Brown	BSI Chief Executive
Dr Jennie Evans	BSI Director of External Affairs
Dr Patrick Cao	Regional Representative - Scotland
Dr Julia Makinde	Regional Representative - England
Dr Dessi Malinova	Regional Representative - Northern Ireland
Dr Simone Cuff	Regional Representative - Wales
Dr Hannah Bradford	Early Career Representative
Dr George Robinson	Early Career Representative
Anna Andrusaite	Early Career Representative
Dr Edoardo Prediletto	Early Career Representative
Dr Chidi Ubachukwu	PhD Representative
Dr Jhanna Kryukova	PhD Representative
Dr Chloe Pyle	Industry Representative
Dr Gareth-Rhys Jones	Clinical Representative
Dr Winnie Ip	Clinical Representative
Dr Rebecca McLean	Veterinary Representative

## Committees

### Congress Committee

Name	Position
Professor Mark Coles	BSI Congress Secretary
Professor Tracy Hussell	BSI President
Dr Fiona Culley	BSI Treasurer
Dr Colin Dayan	BSI Clinical Research Secretary
Dr Edith Hessel	Member
Dr Daniel O'Connor	Early Career Representative
Dr Graham Cook	Member
Dr Helen McGettrick	Member
Dr Henry McSorley	Member
Dr James Harker	Member
Dr James Thaventhiran	Clinical member
Dr Laura Rivino	Member
Dr Margarita Dominguez	Member
Dr Sandra Sacre	Member
Jane Sessenwein	BSI Director of Events & Training

### BSI-CIPN Steering Group

Name	Position
Dr Sinisa Savic	Chair
Dr Suzy Elcombe	Deputy Chair
Dr Catherine Stroud	Membership Lead
Sarah Denman	Pharmacy Representative
Dr Lisa Devlin	Industry Liaison
Jill Edmonds	Nursing Representative
Dr Emma Callery	Healthcare Scientist Representative
Professor Alex Ritcher	Guidelines Lead
Dr Patrick Yong	Training & Education Lead
Dr Manisha Ahuja	Postgraduate Doctor in Training Representative
Dr Leman Mutlu	Patitent Group Liaison
Dr James Thaventhiran	Conference Lead (Co-opted member)
Dr Austen Worth	Paediatric Representative and PID Registry Representative (Ex-officio member)
Dr Claire Bethune	CRG Representative (Ex-officio member)
Dr Sarah Goddard	QPIDS Representative (Ex-officio member)
Dr Tomaz Garcez	BSACI Representative (Ex-officio member)
Dr Doug Brown	BSI Chief Executive

## Journals

### *Clinical and Experimental Immunology* - Editorial Team

Name	Position
Professor Leonie Taams	Editor-in-Chief
Professor Angelo Manfredi	Section Editor - autoimmunity
Professor Tanja de Gruij	Section Editor - cancer immunity
Professor Ciriaco Piccirillo	Section Editor - immune-mediated inflammatory diseases
Dr Cindy Ma	Section Editor - immunodeficiency
Dr Daniel Douek	Section Editor - infectious diseases and vaccines
Professor Xiao-Ning Xu	Section Editor - infectious diseases and vaccines
Professor Sandra Amor	Section Editor - neuroimmunology

### *Immunotherapy Advances* - Editorial Team

Name	Position
Professor Tim Elliot	Editor-in-Chief
Associate Professor Marianne Boes	Deputy Editor
Professor Yiwei Chu	Associate Editor
Dr Stephanie K Dougan	Deputy Editor
Associate Professor Menno van Zelm	Associate Editor

### *Discovery Immunology* - Editorial Team

Name	Position
Professor Simon Milling	Editor-in-Chief
Dr Sophie Acton	Senior Editor
Dr Philip Ahern	Senior Editor
Dr Florent Ginhoux	Senior Editor
Dr Emily Gwyer Findlay	Senior Editor
Dr Lai Guan Ng	Senior Editor
Professor Francisco J. Quintana	Senior Editor
Dr Meera Ramanujam	Senior Editor



## Regional and Affinity groups

### Affinity Groups

Group	Position	Member
Autoimmunity Affinity Group	Chair	Professor Lucy Walker
	Secretary	Dr Kathryn Steel
	Treasurer	Dr James Pearson
Comparative Veterinary Immunology Group	Chair	Wilhelm Gerner
	Secretary	Dr Lindert Benedictus
	Treasurer	Dr Kate Sutton
Immunometabolism Affinity Group	Co-Chair	Dr Laura Pallett
	Co-Chair	Dr Linda Sinclair
	Secretary	Dr Sarah Dimeloe
	Treasurer	Dr Anna Schurich
Immunosenescence Affinity Group	Chair	Dr Sian Henson
	Secretary	Dr Natalie Riddell
	Treasurer	Dr Catarina Henriques
Infection and Immunity Group		
Inflammation Affinity Group	Chair	Professor Peter Barlow
	Treasurer	Dr Joanne Konkel
	Communications	Dr Jack Rivers-Auty
Leukocyte Migration Group	Chair	Dr Myriam Chimen
	Secretary/Treasurer	Dr Graeme O'Boyle
Mathematical Modelling Group	Chair	Dr Grant Lythe
	Secretary	Professor Mark Coles
	Treasurer	Dr Hashem Koohy
Neuroimmunology Group	Chair	Dr Yvonne Dombrowski
	Secretary	Dr Sarosh Irani
Teaching Affinity Group	Co-chair	Professor John Currow
	Co-chair	Dr Nigel Francis
	Secretary	Dr Owen Kavanagh
	Treasurer	Dr Becky Aicheler
Tumour Immunology Affinity Group	Chair	Professor Benjamin Willcox
	Secretary	Dr Seth B. Coffelt
	Treasurer	Professor Awen Gallimore
Vaccine Affinity Group	Chair	Dr Bernardo Villarreal-Ramos
	Secretary	Dr Julia Tree
	Treasurer	Dr Dirk Werling

## Regional and Affinity groups

### Regional Groups

Group	Position	Member
Aberdeen Immunology Group	Chair	Dr Isabel Crane
	Treasurer	Dr Janine Coombes
Bristol Immunology Group	Chair	Dr Gareth Jones
	Secretary	Dr Dronwen Burton
	Treasurer	Dr Lindsay Nicholson
Cambridge Immunology Group	Chair	Dr Brian Ferguson
	Secretary/Treasurer	Dr Louise Boyle
East Anglia Immunology Group	Secretary	Dr Anastasia Sobolewski
	Treasurer	Dr Cristina Fanutti
Edinburgh Immunology Group	Co-Chair	Dr Rebecca Gentek
	Co-Chair	Dr Laura McCulloch
	Secretary	Dr Matthew Burgess
	Secretary	Dr Tovah Shaw
	Treasurer	Dr Sean Wattagedera
Greater Manchester Immunology Group	Chair	Dr Doug Dyer
	Secretary	Dr Andrew Greenhaigh
Immunology North East	Chair	Dr Kevin Marchbank
	Secretary	Dr Antony Antoniou
	Treasurer	Dr Andy Knight
London Immunology Group	Chair	Dr Laura Pallett
	Secretary	Dr Franze Progatezky
	Treasurer	Dr George Finney
Midlands Immunology Group	Chair	Dr Rebecca Drummond
	Treasurer	Dr Martin Davey
Oxford Immunology Group	Chair	Dr Roel De Maeyer
	Secretary	Dr Elena Mitsi
South Wales Immunology Group	Chair	Dr You Zhou
	Secretary	Dr Rebecca Aicheler
	Treasurer	Dr Ceri Fielding

## Regional and Affinity groups

### Regional Groups

Group	Position	Member
Tayside Immunology Group	Chair	Professor Simon Arthur
	Secretary	Dr Mahima Swamy
	Treasurer	Dr Shalini Pathak
Ulster Immunology Group	President	Dr Yvonne Dombrowski
	Secretary	Dr Karim Dib
	Treasurer	Dr Rebecca Coll
Wessex Immunology Group	Co-Chair	Professor Jessica Teeling
	Co-Chair	Dr Sarah Buchan
	Secretary	Dr Alison Hill
	Treasurer	Dr Diogo Silva
West of Scotland Immunology Group	Chair	Dr Megan MacLeod
	Secretary	Dr Ed Roberts
	Treasurer	Dr Hannah Scales
Yorkshire Immunology Group	Chair	Dr Gina Doody
	Secretary	Dr Erica Wilson